| AMENDED CLAIMS received by the International Bureau on 19 July 2019 (19.07.2019) 1. A dipeptidyl peptidase 3 (DPP3) binder directed to and binding to an epitope according to SEQ ID NO.: 2, and wherein said DPP3 binder recognizes and binds to at least three amino acids, particularly to at least four amino acids, more particularly to at least five amino acids of SEQ ID NO.: 2, wherein said epitope is comprised in SEQ ID NO.: 1, and wherein said DPP3 binder exhibit an affinity towards DPP3 in such that the affinity constant is at least 107 M 1. 2. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of claim 1, wherein said DPP3 binder is directed to and binding to an epitope according to SEQ ID NO.: 3, and wherein said DPP3 binder recognizes and binds to at least three amino acids, particularly to at least four amino acids, more particularly to at least five amino acids of SEQ ID NO.: 3. 3. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of claim 1 or claim 2, wherein said DPP3 binder is directed to and binding to an epitope according to SEQ ID NO.: 4, and wherein said DPP3 binder recognizes and binds to at least three amino acids, particularly to the four amino acids of SEQ ID NO.: 4. 4. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the claims 1 to 3, wherein said DPP3 binder is selected from a group comprising an antibody or antibody fragment or non-Ig scaffold. 5. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the claims 1 to 4, wherein said DPP3 binder is selected from a group comprising a monospecific antibody or a monospecific antibody fragment or a monospecific non-Ig scaffold. 6. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding claims, wherein said DPP3 binder is a 96 monoclonal antibody or monoclonal antibody fragment, and wherein the complementarity determining regions (CDR's) in the heavy chain comprises the sequences: SEQ ID NO.: 7, SEQ ID NO.: 8 and/ or SEQ ID NO.: 9 and the complementarity determining regions (CDR's) in the light chain comprises the sequences: SEQ ID NO.: 10, KVS and/or SEQ ID NO.: 11. 7. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding claims, wherein said DPP3 binder is a humanized monoclonal antibody or humanized monoclonal antibody fragment, wherein the heavy chain comprises the sequence: SEQ ID NO.: 12 and wherein the light chain comprises the sequence: SEQ ID NO.: 13. 8. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding claims for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. 9. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to claim 7, wherein said diseases are selected from a group comprising neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, 97 inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS. 10. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to claim 7 or 8, and wherein said: o neurodegenerative disease may be selected from a group comprising Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)), o metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes, o cardiovascular disorder may be selected from a group comprising aterosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction, o autoimmune disease may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus, o inflammatory lung disease may be selected from a group comprising COPD, asthma, o kidney disease may be selected from a group comprising acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD), o liver disease may be selected from a group comprising viral hepatitis, and cirrhosis, o digestive disease may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn’s disease, gastritis, pancreatitis and peptic ulcer, o viral infectious disease may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus, 98 o cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer, o inflammation, o sepsis, septic shock, SIRS. 11. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the claims 7 to 9, wherein said disease is selected from a group comprising sepsis, septic shock, and SIRS. 12. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the claims 7 to 9, wherein said disease is associated with oxidative stress in the myocard. 13. A dipeptidyl peptidase 3 binder directed to and binding to a DPP3 protein or functional derivative thereof for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. 14. The dipeptidyl peptidase 3 binder for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to claim 13, wherein said diseases are selected from a group comprising neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS. 99 15. The dipeptidyl peptidase 3 binder for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the claims 13 or 14, and wherein said: o neurodegenerative disease may be selected from a group comprising Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)), o metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes, o cardiovascular disorder may be selected from a group comprising aterosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction, o autoimmune disease may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus, o inflammatory lung disease may be selected from a group comprising COPD, asthma, o kidney disease may be selected from a group comprising acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD), o liver disease may be selected from a group comprising viral hepatitis, and cirrhosis, o digestive disease may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn’s disease, gastritis, pancreatitis and peptic ulcer, o viral infectious disease may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency vims (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus, o cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer, o inflammation, o sepsis, septic shock, SIRS. 100 |
Next Patent: PRESTRESSING DEVICE